US Map / Arkansas
State AR

Clinical Trials in Arkansas

Arkansas is home to a significant concentration of clinical research activity, with academic medical centers, community hospitals, and specialized research clinics serving as active trial sites across a broad range of medical conditions. The studies listed here have at least one enrolled site in Arkansas and represent Phase 1 through Phase 4 research sponsored by NIH, pharmaceutical companies, device manufacturers, and independent investigators.

Right now ClinicalMetric tracks 99 actively recruiting studies with Arkansas sites out of 99 registered in total. The busiest research areas in Arkansas are Schizophrenia, Acute Myeloid Leukemia, Atrial Fibrillation. Leading sponsors running trials in the state include SWOG Cancer Research Network, Novartis Pharmaceuticals, National Cancer Institute (NCI). By stage, Arkansas trials break down as Phase 1 (9), Phase 2 (25), Phase 3 (44), Phase 4 (4).

All trial data is sourced directly from ClinicalTrials.gov and updated daily. Recruiting status, eligibility criteria, enrollment targets, and contact information are included for each study. Patients and caregivers should review the full eligibility criteria on each trial listing — or consult their treating physician — before contacting a study site.

Total Trials
99
Recruiting Now
99
← Back to US Map
Top Conditions in Arkansas
Schizophrenia (3)Acute Myeloid Leukemia (3)Atrial Fibrillation (2)Non-small Cell Lung Cancer (2)Dravet Syndrome (2)Malignant Solid Neoplasm (2)Stage III Pancreatic Cancer AJCC v8 (2)Stage IV Pancreatic Cancer AJCC v8 (2)Duchenne Muscular Dystrophy (2)Peanut Allergy (2)Type 2 Diabetes Mellitus (2)Malignant Melanoma (1)

Frequently Asked Questions — Clinical Trials in Arkansas

How many clinical trials are currently recruiting in Arkansas?
ClinicalMetric currently tracks 99 actively recruiting clinical trials with at least one location in Arkansas. The total number of registered studies—including active but not currently enrolling trials—is 99. Trial availability is updated daily from ClinicalTrials.gov, and new studies open enrollment regularly throughout the year.
What types of clinical trials are available in Arkansas?
Arkansas hosts clinical trials across a broad range of medical conditions, including Schizophrenia, Acute Myeloid Leukemia, Atrial Fibrillation, and many others. Trials range from Phase 1 early-safety studies to Phase 4 post-approval surveillance, as well as observational and behavioral research. Academic medical centers, community hospitals, and specialized research clinics throughout Arkansas serve as trial sites for studies sponsored by NIH, pharmaceutical companies, and independent investigators.
How do I join a clinical trial near me in Arkansas?
To join a clinical trial in Arkansas, browse the recruiting studies listed on this page, review the eligibility criteria for each trial, and contact the study site directly. Your primary care physician or specialist can also refer you to clinical trials relevant to your diagnosis. Many academic medical centers in Arkansas maintain dedicated clinical trials offices that can match you with appropriate studies based on your medical profile and diagnosis.

Recruiting Trials in Arkansas

NCT06961006 Phase 2
Recruiting
A Clinical Study of Intismeran Autogene (V940) and Pembrolizumab (MK-3475) in Pe...
Condition
Malignant Melanoma
Enrollment
160 pts
Location
United States, Australia, Canada
Sponsor
Merck Sharp & Dohme LLC
View Trial →
NCT07539155 Phase 1, Phase 2
Recruiting
Intratumoral MMR Vaccine Injection in Borderline Resectable/Unresectable Pancrea...
Condition
Borderline Resectable/Unresectable Pancreatic Cancer
Enrollment
20 pts
Location
United States
Sponsor
University of Arkansas
View Trial →
NCT04299191 Phase 1, Phase 2
Recruiting
Study of LAM561 Acid in Pediatric Patients With Malignant Glioma and Other Advan...
Condition
High-grade Glioma
Enrollment
28 pts
Location
United States
Sponsor
Laminar Pharmaceuticals
View Trial →
NCT06617325 Phase 3
Recruiting
A Study to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Study Part...
Condition
Systemic Lupus Erythematosus
Enrollment
450 pts
Location
United States, Argentina, Belgium
Sponsor
UCB Biopharma SRL
View Trial →
NCT04079179 Phase 2
Recruiting
Cobimetinib in Refractory Langerhans Cell Histiocytosis (LCH), and Other Histioc...
Condition
Langerhan's Cell Histiocytosis
Enrollment
90 pts
Location
United States
Sponsor
Carl Allen
View Trial →
NCT06875973 Phase 3
Recruiting
Pelacarsen Roll-over Extension Program
Condition
Atherosclerotic Cardiovascular Disease
Enrollment
599 pts
Location
United States, Puerto Rico
Sponsor
Novartis Pharmaceuticals
View Trial →
NCT06072781 Phase 3
Recruiting
A Study of Avutometinib (VS-6766) + Defactinib (VS-6063) in Recurrent Low-Grade ...
Condition
Low Grade Serous Ovarian Cancer
Enrollment
270 pts
Location
United States, Australia, Belgium
Sponsor
Verastem, Inc.
View Trial →
NCT07300969 Phase 2
Recruiting
A Study to Evaluate the Effectiveness of DT-101 in Patients With Depression
Condition
Major Depressive Disorder (MDD)
Enrollment
300 pts
Location
United States, Bulgaria, Czechia
Sponsor
Draig Therapeutics Ltd
View Trial →
NCT03723928 N/A
Recruiting
S1703 Serum Tumor Marker Directed Disease Monitoring in Patients With Hormone Re...
Condition
Anatomic Stage IV Breast Cancer AJCC v8
Enrollment
739 pts
Location
United States, Guam, Puerto Rico
Sponsor
SWOG Cancer Research Network
View Trial →
NCT07527299 N/A
Recruiting
A Study of VARIPULSE Catheter in Participants With Persistent Atrial Fibrillatio...
Condition
Atrial Fibrillation
Enrollment
1,070 pts
Location
United States
Sponsor
Biosense Webster, Inc.
View Trial →
NCT04166409 Phase 3
Recruiting
A Study of the Drugs Selumetinib vs. Carboplatin and Vincristine in Patients Wit...
Condition
Low Grade Astrocytoma
Enrollment
170 pts
Location
United States, Canada, Puerto Rico
Sponsor
National Cancer Institute (NCI
View Trial →
NCT07165028 Phase 3
Recruiting
A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associ...
Condition
Metabolic Dysfunction-Associated Steatotic Liver Disease
Enrollment
4,500 pts
Location
United States, Argentina, Australia
Sponsor
Eli Lilly and Company
View Trial →
NCT05762107 Phase 2
Recruiting
A Study of the Effect of ZT-01 on Night-time Hypoglycemia in Type 1 Diabetes
Condition
Type 1 Diabetes Mellitus With Hypoglycemia
Enrollment
186 pts
Location
United States, Canada
Sponsor
Zucara Therapeutics Inc.
View Trial →
NCT07217301 Phase 3
Recruiting
A Study Comparing TAK-928 With Docetaxel in Adults With Non-Small Cell Lung Canc...
Condition
IO-resistant sqNSCLC
Enrollment
600 pts
Location
United States, China, Japan
Sponsor
Takeda
View Trial →
NCT01524276 N/A
Recruiting
Product Surveillance Registry
Condition
Cardiac Rhythm Disorders
Enrollment
100,000 pts
Location
United States, Argentina, Australia
Sponsor
Medtronic
View Trial →
NCT05778188 Phase 2
Recruiting
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary ...
Condition
Hypoxic-Ischemic Encephalopathy
Enrollment
70 pts
Location
United States
Sponsor
ReAlta Life Sciences, Inc.
View Trial →
NCT07717892 Phase 3
Recruiting
Forward Treatment of Attention Deficit and Hyperactivity Using Solriamfetol (FOC...
Condition
ADHD
Enrollment
468 pts
Location
United States
Sponsor
Axsome Therapeutics, Inc.
View Trial →
NCT06218875 N/A
Recruiting
Endovascular AAA Intervention Using the GORE® EXCLUDER® Conformable AAA Endopros...
Condition
AAA - Abdominal Aortic Aneurysm
Enrollment
2,000 pts
Location
United States, Australia, Austria
Sponsor
W.L.Gore & Associates
View Trial →
NCT01904851 N/A
Recruiting
Multi-Center Registry for Peripheral Arterial Disease Interventions and Outcomes
Condition
Peripheral Arterial Disease
Enrollment
14,000 pts
Location
United States
Sponsor
Baylor Research Institute
View Trial →
NCT05125302 Phase 3
Recruiting
Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets f...
Condition
Migraine
Enrollment
1,059 pts
Location
United States, Puerto Rico
Sponsor
AbbVie
View Trial →
NCT06692738 Phase 3
Recruiting
A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for...
Condition
Non-small Cell Lung Cancer
Enrollment
1,160 pts
Location
United States, Argentina, Australia
Sponsor
AstraZeneca
View Trial →
NCT05624996 Phase 3
Recruiting
Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for...
Condition
Locally Advanced Lung Non-Small Cell Carcinoma
Enrollment
474 pts
Location
United States, Canada
Sponsor
NRG Oncology
View Trial →
NCT07467993 Phase 2
Recruiting
Study to Assess the Safety, Tolerability, and Treatment Response of GXV813 in Ho...
Condition
Schizophrenia
Enrollment
142 pts
Location
United States, Bulgaria
Sponsor
Novartis Pharmaceuticals
View Trial →
NCT06745908 Phase 3
Recruiting
Clinical Trial of N-803 Plus Tislelizumab or Prior Failed Immune Checkpoint Inhi...
Condition
NSCLC Stage IV
Enrollment
507 pts
Location
United States, Canada, United Kingdom
Sponsor
ImmunityBio, Inc.
View Trial →
NCT06872125 Phase 3
Recruiting
A Double-blind Study Evaluating the Efficacy, Safety, and Tolerability of Zorevu...
Condition
Dravet Syndrome
Enrollment
170 pts
Location
United States, China, France
Sponsor
Stoke Therapeutics, Inc
View Trial →
Page 1 of 4 — 99 trials total
Next →
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: September 2026  ·  Data Methodology